Citigroup Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $26
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Geoff Meacham maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $20 to $26.
Citigroup analyst Geoff Meacham maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $20 to $26.